TXG 10X GENOMICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, 10X GENOMICS INC reported revenue of $151M (down 12.6% from a year earlier), net income of −$17.9M and diluted EPS of −$0.14; over the last four quarters revenue was $617M and net income −$75.1M; for the fiscal year ended December 2025 revenue was $643M, up 5.2% on the year before.

TXG annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $643M, gross profit $444M, operating income −$61.0M, net income −$43.5M (margin -6.8%), EPS −$0.35
• Fiscal year ended Dec 2024: revenue $611M, gross profit $414M, operating income −$195M, net income −$183M (margin -29.9%), EPS −$1.52
• Fiscal year ended Dec 2023: revenue $619M, gross profit $409M, operating income −$265M, net income −$255M (margin -41.2%), EPS −$2.18
• Fiscal year ended Dec 2022: revenue $516M, gross profit $396M, operating income −$168M, net income −$166M (margin -32.1%), EPS −$1.46
• Fiscal year ended Dec 2021: revenue $490M, gross profit $416M, operating income −$52.3M, net income −$58.2M (margin -11.9%), EPS −$0.53

TXG quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $151M (down 12.6% year over year), net income −$17.9M, EPS −$0.14
• Quarter ended Mar 31, 2026: revenue $151M (down 2.6% year over year), net income −$13.5M, EPS −$0.10
• Quarter ended Dec 31, 2025 (from the annual report): revenue $166M (up 0.6% year over year), net income −$16.2M, EPS −$0.13
• Quarter ended Sep 30, 2025: revenue $149M (down 1.7% year over year), net income −$27.5M, EPS −$0.22
• Quarter ended Jun 30, 2025: revenue $173M (up 12.9% year over year), net income $34.5M, EPS $0.28
• Quarter ended Mar 31, 2025: revenue $155M (up 9.8% year over year), net income −$34.4M, EPS −$0.28
• Quarter ended Dec 31, 2024 (from the annual report): revenue $165M (down 10.3% year over year), net income −$49.0M, EPS −$0.40
• Quarter ended Sep 30, 2024: revenue $152M (down 1.3% year over year), net income −$35.8M, EPS −$0.30
• Quarter ended Jun 30, 2024: revenue $153M (up 4.3% year over year), net income −$37.9M, EPS −$0.32
• Quarter ended Mar 31, 2024: revenue $141M (up 5.0% year over year), net income −$59.9M, EPS −$0.50
• Quarter ended Dec 31, 2023 (from the annual report): revenue $184M (up 17.8% year over year), net income −$49.0M, EPS −$0.42
• Quarter ended Sep 30, 2023: revenue $154M (up 17.2% year over year), net income −$93.0M, EPS −$0.79
• Quarter ended Jun 30, 2023: revenue $147M (up 28.1% year over year), net income −$62.4M, EPS −$0.53
• Quarter ended Mar 31, 2023: revenue $134M (up 17.3% year over year), net income −$50.7M, EPS −$0.44
• Quarter ended Dec 31, 2022 (from the annual report): revenue $156M (up 8.8% year over year), net income −$17.2M, EPS −$0.14
• Quarter ended Sep 30, 2022: revenue $131M (up 4.6% year over year), net income −$41.9M, EPS −$0.37
• Quarter ended Jun 30, 2022: revenue $115M (down 1.1% year over year), net income −$64.5M, EPS −$0.57
• Quarter ended Mar 31, 2022: revenue $114M (up 8.2% year over year), net income −$42.4M, EPS −$0.38
• Quarter ended Dec 31, 2021 (from the annual report): revenue $144M, net income −$18.4M, EPS −$0.17
• Quarter ended Sep 30, 2021: revenue $125M, net income −$17.2M, EPS −$0.15

TXG cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $136M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $6.66M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$15.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$33.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$21.4M, share buybacks n/a

TXG balance sheet

• Jun 30, 2026: cash n/a, total assets $1.03B, total liabilities $205M, shareholders' equity $826M
• Mar 31, 2026: cash n/a, total assets $1.02B, total liabilities $201M, shareholders' equity $814M
• Dec 31, 2025: cash n/a, total assets $1.04B, total liabilities $245M, shareholders' equity $796M
• Sep 30, 2025: cash n/a, total assets $1.03B, total liabilities $242M, shareholders' equity $785M
• Jun 30, 2025: cash n/a, total assets $980M, total liabilities $207M, shareholders' equity $773M
• Mar 31, 2025: cash n/a, total assets $903M, total liabilities $196M, shareholders' equity $707M
• Dec 31, 2024: cash $344M, total assets $919M, total liabilities $209M, shareholders' equity $710M
• Sep 30, 2024: cash n/a, total assets $938M, total liabilities $215M, shareholders' equity $723M

What is TXG's revenue?

10X GENOMICS INC reported $617M of revenue over its last four quarters, through June 30, 2026.

Is TXG profitable?

No. 10X GENOMICS INC lost $75.1M over the last four quarters.

What is TXG's EPS?

Diluted earnings per share over the last four quarters were −$0.59; −$0.14 in the latest quarter.

TXG ownership and insider trades · All stocks